O

Oragenics
D

OGEN

1.13000
USD
-0.04
(-3.42%)
مغلق
حجم التداول
631
الربح لكل سهم
-11
العائد الربحي
-
P/E
-0
حجم السوق
929,908
أصول ذات صلة
A
ALT
-0.05500
(-1.50%)
3.62000 USD
A
ATOS
-0.00820
(-1.04%)
0.77680 USD
AXON
AXON
4.59
(0.61%)
754.42 USD
C
CLRB
-0.02000
(-0.46%)
4.35000 USD
C
CYCC
-0.97000
(-10.95%)
7.89000 USD
المزيد
الأخبار المقالات

العنوان: Oragenics

القطاع: Healthcare
الصناعة: Biotechnology
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.